Hims & Hers acquires Eucalyptus in $1.15B global healthcare expansion

Hims & Hers Health (HIMS) has agreed to buy Australian digital health firm Eucalyptus for up to $1.15 billion. The deal marks a major expansion for the US-based company into new international markets, including the stock market today. Eucalyptus currently serves over 775,000 customers and generates nearly $450 million in annual revenue.

The acquisition will see Eucalyptus join Hims & Hers, bringing its well-known brands like Juniper and Pilot under the US company's umbrella. The deal includes $240 million in cash upfront, with additional deferred payments and performance-related earnouts stretching over 18 months and into early 2029.

Once finalised, Eucalyptus CEO Tim Doyle will take charge of Hims & Hers' international operations. The move significantly broadens the company's reach, adding Australia and Japan to its existing markets, further strengthening its position in the stock market. It also strengthens Hims & Hers' position in the UK, Germany, and Canada.

Eucalyptus has built a strong customer base, with over 775,000 users and an annual revenue approaching $450 million. The acquisition aligns with Hims & Hers' strategy to grow its global footprint in digital healthcare services.

The purchase of Eucalyptus will extend Hims & Hers' presence across five key markets. With Tim Doyle leading international operations, the company aims to integrate the Australian firm's brands and customer base. The deal's structure includes upfront cash, deferred payments, and performance incentives over the next few years, making it an attractive proposition for investors in the stock market today.